Quarterly ResultAug 6, 2026, 08:01 AM
Agenus Reports Q2 2026 Results; Advances Phase 3 ROBBIN Trial
AI Summary
Agenus reported its second quarter 2026 financial results, with total revenue increasing to $34.5 million from $25.7 million year-over-year, including $6.4 million in pre-commercial product revenue. The company is advancing its Phase 3 ROBBIN trial for BOT+BAL in neoadjuvant MSS colon cancer, targeting an estimated $7 billion annual U.S. sales opportunity. This initiative is supported by a recently completed $85 million private placement, with potential for an additional $255 million from milestone-aligned warrants, expected to fund operations through year-end 2031 if fully exercised. ROBBIN trial initiation and first patient dosing are anticipated in Q1 2027.
Key Highlights
- Phase 3 ROBBIN trial for BOT+BAL in MSS colon cancer targets an estimated annual U.S. sales opportunity of more than $7 billion.
- Agenus completed an oversubscribed private placement providing $85 million in upfront gross proceeds.
- Milestone-aligned warrants could provide up to $255 million in additional gross proceeds if fully exercised.
- Total revenue for Q2 2026 was $34.5 million, compared with $25.7 million a year earlier.
- Pre-commercial BOT+BAL product revenue was $6.4 million in Q2 2026, up from $4.6 million in Q1 2026.
- Non-cash royalty revenue was $28.1 million in Q2 2026, up from $24.8 million in Q2 2025.
- ROBBIN trial initiation and first patient dosing are anticipated in the first quarter of 2027.
- Financing expected to support operations through Q3 2027 with upfront proceeds, and through year-end 2031 if warrants are fully exercised.
Price Impact
More from AGEN